Regulatory Oversight, Innovation, and Access in Aortic Dissection Care: The Evolving Roles of the FDA, CMS

Key Points

• Access to effective aortic dissection treatments is influenced greatly by regulatory oversight and innovation pathways.
• Key regulatory bodies, including the FDA and CMS, play critical roles in approving and facilitating new therapies for aortic dissection.
• This analysis examines the evolving interaction between innovation in treatment and regulatory oversight across different healthcare settings.
• Findings suggest that improved access to care requires ongoing collaboration between regulatory entities and innovators.